Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology
Published in: Inflammopharmacology 2/2024

03-02-2024 | Polio Virus | Original Article

Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines

Authors: Guojuan Sun, Guangzhi Wang, Heng Zhong

Published in: Inflammopharmacology | Issue 2/2024

Login to get access

Abstract

Background

This study aimed to evaluate the immunogenicity and safety of different types of poliovirus vaccines.

Methods

A randomized, blinded, single-center, parallel-controlled design was employed, and 360 infants aged ≥ 2 months were selected as study subjects. They were randomly assigned to bOPV group (oral Sabin vaccine) and sIPV group (Sabin strain inactivated polio vaccine), with 180 infants in each group. Adverse reaction events in the vaccinated subjects were recorded. The micro-neutralization test using cell culture was conducted to determine the geometric mean titer (GMT) of neutralizing antibodies against poliovirus types I, II, and III in different groups, and the seroconversion rates were calculated.

Results

Both groups exhibited a 100% seropositivity rate after booster immunization. The titers of neutralizing antibodies for the three types were predominantly distributed within the range of 1:128 to 1:512. The fold increase of type I antibodies differed markedly between the two groups (P < 0.05). Moreover, the fold increase of type II and type III antibodies for poliovirus differed slightly between the two groups (P > 0.05). The fourfold increase rate in sIPV group was drastically superior to that in bOPV group (P < 0.05). When comparing the post-immunization GMT levels of type I antibodies in individuals who completed the full course of spinal muscular atrophy vaccination, bOPV group showed greatly inferior levels to sIPV group (P < 0.05). For type II and type III antibodies, individuals in bOPV group demonstrated drastically superior post-immunization GMT levels to those in sIPV group (P < 0.05). The incidence of adverse reactions between the bOPV and sIPV groups differed slightly (P > 0.05).

Conclusion

These findings indicated that both the oral vaccine and inactivated vaccine had good safety and immunogenicity in infants aged ≥ 2 months. The sIPV group generated higher levels of neutralizing antibodies in serum, particularly evident in the post-immunization GMT levels for types II and III.
Literature
Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, Sambou NA, Fofana S, Kanu FJ, Jeyaseelan V, Verma H, Weldon WC, Oberste MS, Sutter RW, Jeffries D, Wathuo M, Mach O, Clarke E (2022) Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. Lancet Glob Health 10:e257–e268PubMedCrossRef
Bayliss J, Nissen M, Prakash D, Richmond P, Oh KB, Nolan T (2021) Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Hum Vaccin Immunother 17:176–190PubMedCrossRef
Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora CFCB, Thierry-Carstensen B, Tingskov PN, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV (2020) Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: a phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine 38:530–538PubMedPubMedCentralCrossRef
Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S (2020) Safety and immunogenicity of Vi-DT conjugate vaccine among 6–23-month-old children: phase II, randomized, dose-scheduling, observer-blind study. EClinicalMedicine 27:100540PubMedPubMedCentralCrossRef
Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, Han S, Wittawatmongkol O (2022) Safety and immunogenicity of a new inactivated polio vaccine made from sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis 226:308–318PubMedCrossRef
Chumakov K, Ehrenfeld E, Agol VI, Wimmer E (2021) Polio eradication at the crossroads. Lancet Glob Health 9:e1172–e1175PubMedCrossRef
Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Sáez-Llorens X (2020) Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: a randomized, observer-blind, controlled phase 1/2 trial. Vaccine 38:5313–5323PubMedPubMedCentralCrossRef
Dakin A, Borrow R, Arkwright PD (2023) A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients. Expert Rev Vaccines 22:104–117PubMedCrossRef
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P (2021) Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 397:39–50PubMedPubMedCentralCrossRef
Leo DE, Cappelli V, Massaro MG, Tosti C, Morgante G (2017) Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women. Minerva Ginecol 69:336–341PubMed
Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, Perminova O, Kobashi IAR, Bae CW, Ojeda J, Park J, Chansinghakul D, B’Chir S, Neveu D, Bonaparte M, Jordanov E (2021) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect 149:e90PubMedPubMedCentralCrossRef
Duintjer Tebbens RJ, Thompson KM (2018) Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 17:739–751PubMedPubMedCentralCrossRef
Fadlyana E, Dhamayanti M, Tarigan R, Mulia Sari R, Sjafri Bachtiar N, Kartasasmita CB, Rusmil K (2020) Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Vaccine 38:1962–1967PubMedCrossRef
Falleiros-Arlant LH, Ayala SEG, Domingues C, Brea J, Colsa-Ranero A (2020) Current status of poliomyelitis in Latin America. Rev Chilena Infectol 37:701–709PubMedCrossRef
Feng G, Jiang D, Han W, Xie Z, Jiang Z, Huang L, Wang J, Zhang W, Xu L, Tan J, You W, Cui G, Li C, Wang Y (2023) Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. Int J Infect Dis 130:20–27PubMedCrossRef
Ferlito C, Visco V, Biselli R, Cattaruzza MS, Carreras G, Salerno G, Lista F, Capobianchi MR, Castilletti C, Lapa D, Antonelli G, Gentile M, Sorice M, Riitano G, Lucania G, Riccieri V, Mainiero F, Angeloni A, Lucarelli M, Ferraguti G, Autore A, Lastilla M, Salemi S, Biondo MI, Picchianti-Diamanti A, Caporuscio S, Teloni R, Mariotti S, Nisini R, D’Amelio R (2021) Safety of multiple vaccinations and durability of vaccine-induced antibodies in an Italian military cohort 5 years after immunization. Biomedicines 10:6PubMedPubMedCentralCrossRef
Fukushima S, Nakano T, Shimizu H, Hamada A (2022) Immunogenicity of catch-up immunization with conventional inactivated polio vaccine among Japanese adults. Vaccines (basel) 10:2160PubMedCrossRef
Gao S, Wei M, Chu K, Li J, Zhu F (2022) Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Hum Vaccin Immunother 18:2050106PubMedPubMedCentralCrossRef
GBD (2020) Release 1, vaccine coverage collaborators (2021) measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the global burden of disease study 2020, release 1. Lancet 398:503–521
Jaiswal N, Singh S, Agarwal A, Chauhan A, Thumburu KK, Kaur H, Singh M (2019) Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database Syst Rev 12:CD011780PubMed
Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M (2021) Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 39:1463–1471PubMedCrossRef
Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, Fall G, Dia M, Bob NS, Monath TP, Barrett AD, Hombach J, Mulogo EM, Ampeire I, Karanja HK, Nyehangane D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF (2021) Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 397:119–127PubMedPubMedCentralCrossRef
Li Z, Xu J, Tan H, Zhang C, Chen J, Ni L, Yun X, Huang Y, Wang W (2020) Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis 99:149–155PubMedCrossRef
Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, Yang J, Yin Z, Wang J, Chu J, Cai W, Zhou J, Wang J, Li Q (2016) Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine. J Infect Dis 214:1728–1734PubMedCrossRef
Liu B, Cao B, Wang C, Han B, Sun T, Miao Y, Lu Q, Cui F (2022) Immunogenicity and safety of childhood combination vaccines: a systematic review and meta-analysis. Vaccines (basel) 10:472PubMedCrossRef
Lohiniva AL, Nurzhynska A, Alhassan H, Shetye M, Ayiku P (2022) Understanding factors influencing polio vaccine uptake in Ghana-developing meaningful community mobilization and engagement strategies in collaboration with religious leaders. Am J Trop Med Hyg 107:1345–1350PubMedPubMedCentralCrossRef
Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F (2022) Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India. Vaccine X 11:100190PubMedPubMedCentralCrossRef
Mansoor I, Eassa HA, Mohammed KHA, Abd El-Fattah MA, Abdo MH, Rashad E, Eassa HA, Saleh A, Amin OM, Nounou MI, Ghoneim O (2022) Microneedle-based vaccine delivery: review of an emerging technology. AAPS PharmSciTech 23:103PubMedCrossRef
Modlin JF, Bandyopadhyay AS, Sutter R (2021) Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication. J Infect Dis 224:S398–S404PubMedPubMedCentralCrossRef
Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H (2020) Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. J Infect Chemother 26:651–659PubMedCrossRef
Qiu X, Chen K, Tong L, Shu X, Lü X, Wen H, Deng C (2004) Effects of moxibustion at shenque (CV 8) on serum IL-12 level and NK cell activities in mice with transplanted tumor. J Tradit Chin Med 24:56–58PubMed
Sáez-Llorens X, Chan M, DeAntonio R, Petersen T, Olesen C, Jensen JS, Sørensen C, Ekstrand LM, Czort MK, Kristensen HH, Thulstrup N, Christoffersen DB (2022) Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. Vaccine 40:5835–5841PubMedPubMedCentralCrossRef
Sharma H, Lalwani S, Parekh S, Pujari P, Shewale S, Palkar S, Hanumante N, Gokhale S, Ks J, Kumar R, Sharma I, Gairola S (2022) A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months. Hum Vaccin Immunother 18:2146435PubMedPubMedCentralCrossRef
Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Bougouma EC, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Oshinsky JJ, Pasetti MF, Neuzil KM, Laurens MB (2021a) Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis 108:465–472PubMedPubMedCentralCrossRef
Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MB (2021b) Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. Int J Infect Dis 102:517–523PubMedPubMedCentralCrossRef
Sultan MA (2022) Emerging challenges to realizing global polio eradication and their solutions. East Mediterr Health J 28:515–520CrossRef
Sun X, Xu Y, Tang F, Xiao Y, Wang Z, Wang B, Zhu X, Yang X, Chen H (2022) Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: a multicenter, randomized, non-inferiority, controlled trial. Front Immunol 13:905634PubMedPubMedCentralCrossRef
Thompson KM, Kalkowska DA (2021) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 41:229–247PubMedCrossRef
Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P (2018) Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr 172:1045–1052PubMedPubMedCentralCrossRef
Yang K, Kim H, Ortiz E, Huoi C, Kang J (2023) Post-marketing safety surveillance of a childhood pentavalent diphtheria-tetanus-acellular pertussis-polio and haemophilus influenzae type B (DTaP-IPV//Hib) vaccine in South Korea. Infect Dis Ther 12:499–511PubMedCrossRef
Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, Mainou BA, Konopka-Anstadt JL, Hendley WS, Vincent A, Clemens R, Clemens SAC, Ross AG, Clemens JD, Tritama E (2023) Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet 401:131–139PubMedPubMedCentralCrossRef
Zhang Y, Guo Y, Dong Y, Liu Y, Zhao Y, Yu S, Li S, Wu C, Yang B, Li W, Wei X, Zhang Y, Huang Y, Wang H, Yang X (2022) Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models. Hum Vaccin Immunother 18:2160158PubMedPubMedCentralCrossRef
Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, Ye H, Zhao Z, Liu X, Li J, Li Y, Li R, Jiang R, Wang J, Fu Y, Ma R, Shi H, Yang H, Li C, Yang J, Li Q (2021) Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med 9:253PubMedPubMedCentralCrossRef
Zheng Y, Ying Z, Zou Y, Zhu T, Qian D, Han W, Jiang Y, Jiang Z, Li X, Wang J, Lei J, Xu L, Jiang D, Li C, Liu X (2022) Safety, immunogenicity and lot-to-lot consistency of sabin-strain inactivated poliovirus vaccine in 2-month-old infants: a double-blind. Randomized phase III trial. Vaccines (basel) 10:254PubMedCrossRef
Metadata
Title
Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines
Authors
Guojuan Sun
Guangzhi Wang
Heng Zhong
Publication date
03-02-2024
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 2/2024
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01395-7

Other articles of this Issue 2/2024

Inflammopharmacology 2/2024 Go to the issue

Original Article

Neuroprotective mechanism of trans,trans-Farnesol in an ICV-STZ-induced rat model of Alzheimer’s pathology

Original Article

Leaf extracts of eight selected southern African medicinal plants modulate pro-inflammatory cytokine secretion in LPS-stimulated RAW 264.7 macrophages

Correction

Correction to: Chrysophanol exerts a protective effect against Aβ25‑35‑induced Alzheimer’s disease model through regulating the ROS/TXNIP/NLRP3 pathway

Original Article

Glabridin reduces neuroinflammation by modulating inflammatory signals in LPS-induced in vitro and in vivo models

Original Article

Antinociceptive and anti-inflammatory activity of extracts and α-pyrones isolated from Cantinoa stricta

Original Article

Synthesis of novel nonsteroidal anti-inflammatory galloyl β-sitosterol-loaded lignin-capped Ag-based drug